

CRITICAL REVIEWS™ IN ONCOGENESIS

INDEX VOLUME 21, 2016

Page Range of Issues:
Issues 1-2: 1-154; Issue 3-4: 155-308; Issue 5-6: 309-458

ISSUES 1-2

Special Issue: The Living Legacy of Donald L. Morton
Guest Editor: Dave S. B. Hoon

Donald L. Morton, MD 1934–2014 <i>D.S.B. Hoon</i>	1
Donald L. Morton, MD.... A Legendary Surgical Oncologist and Consummate Investigator <i>C.M. Balch & D.S.B. Hoon</i>	3
Sentinel Lymph Node Biopsy: Evolution of the Technique since the Original Description by Morton et al. in 1992 <i>R.F. Uren, O.E. Nieweg, & J.F. Thompson</i>	7
Surgical Lymphadenectomy: The Impact of Sentinel Node Mapping in Breast Cancer <i>S.L. Chen</i>	19
A Comprehensive Approach to Pediatric Atypical Melanocytic Neoplasms with Comment on the Role of Sentinel Lymph Node Biopsy <i>V.K. Sondak, D. Reed, & J.L. Messina</i>	25
Metastasectomy for Stage IV Melanoma in the Era of Effective Systemic Agents <i>D.W. Ollila, N.E. Lopez, & E.C. Hsueh</i>	37
Immunology Comes Full Circle in Melanoma while Specific Immunity is Unleashed to Eliminate Metastatic Disease, Inflammatory Products of Innate Immunity Promote Resistance <i>E.A. Grimm</i>	57
Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology <i>M.B. Faries</i>	65
Therapeutic Strategies for Human IgM Antibodies Directed at Tumor-Associated Ganglioside Antigens: Discoveries Made during the Morton Era and Future Directions <i>P.C. Jones & R.F. Irie</i>	75
Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy? <i>M.C. Kelley</i>	83
Hepatocellular Carcinoma: The Current Role of Surgical Intervention <i>S.D. Colquho</i>	93
Surgical Resection of Retroperitoneal Sarcomas: Analysis of Factors Determining Outcome <i>F. Amersi, C. Forscher, & A.W. Silberman</i>	105
Gene Therapy for Lung Cancer <i>H. Lara-Guerra & J. Roth</i>	115
Circulating Tumor Cells in Breast Cancer Patients <i>C. Hall, L. Valad, & A. Lucci</i>	125
Liquid Biopsies for Assessing Metastatic Melanoma Progression <i>K. Huynh & D.S.B. Hoon</i>	141

ISSUES 3-4

Special Issue: Focus on Cell Death
Guest Editor: Alex Philchenkov

Anoikis and EMT: Lethal “Liaisons” during Cancer Progression <i>Z. Cao, T. Livas, & N. Kyprianou</i>	155
--	-----

The Role of the Apoptotic Machinery in Ionizing Radiation-Induced Carcinogenesis	169
<i>E.K. Balcer-Kubiczek</i>	
The IAP Protein Family, SMAC Mimetics, and Cancer Treatment	185
<i>A. Philchenkov & K. Miura</i>	
Resistance to Cell Death and Its Modulation in Cancer Stem Cells	203
<i>A.R. Safa</i>	
Engaging Cell Death Pathways for the Treatment of Rhabdomyosarcoma	221
<i>C.C. Dobson, S. Langlois, D. Grynszpan, K.N. Cowan, & M. Holcik</i>	
Targeting Autophagy in Glioblastoma	241
<i>J. Noonan, J. Zarrer, & B.M. Murphy</i>	
Cell Death Induction in Cancer Therapy— Past, Present, and Future	253
<i>L. Nonnenmacher, S. Hasslacher, J. Zimmermann, G. Karpel-Masster, K. La Ferla-Brühl, S.E. Barry, T. Burster, M.D. Siegelin, O. Brühl, M-E. Halatsch, K-M Debatin, & M-A Westhoff</i>	
Strategies to Strike Survival Networks in Cancer	269
<i>M. Pennati, G. Cimino-Reale, L. Gatti, & G. Cassinelli</i>	

ISSUES 5-6

Special Issue: Nitric Oxide and Cancer

Guest Editor: Valentina Rapozzi & Greta Varchi

Special Issue: Nitric Oxide and Cancer: Pathological and Therapeutic Aspects	v
<i>V. Rapozzi & G. Varchi</i>	
Highlights of the Fifth International Workshop on Nitric Oxide and Cancer	309
<i>V. Rapozzi, C. Ferroni, & G. Varchi</i>	
Nitric Oxide and PGE-2 Cross-Talk in EGFR-Driven Epithelial Tumor Cells	325
<i>S. Donnini, L. Bazzani, M. Ziche, & E. Terzuoli</i>	
Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes	333
<i>E.M. Walsh, M.M. Keane, D.A. Wink, G. Callagy, & S.A. Glynn</i>	
Role of Endogenous Nitric Oxide in Hyperaggressiveness of Tumor Cells that Survive a Photodynamic Therapy Challenge	353
<i>A.W. Girotti</i>	
Nitric Oxide's Contribution to Selective Apoptosis Induction in Malignant Cells through Multiple Reaction Steps	365
<i>G. Bauer</i>	
IAPs: Mediators of Oncogenesis and Targets for Anticancer Therapy	399
<i>S. Bouaouiche, L. Dubrez, A. Bettaieb, & S. Plenchette</i>	
Antitumoral Activity of Sorafenib in Hepatocellular Carcinoma: Effects on Cell Survival and Death Pathways, Cell Metabolism Reprogramming, and Nitrosative and Oxidative Stress	413
<i>F.J. Molina-Ruiz, R. González, M.A. Rodríguez-Hernández, E. Navarro-Villarán, F.J. Padillo, & J. Muntané</i>	
Tumor Suppressor Roles of the Denitrosylase GSNOR	433
<i>S. Rizza & G. Filomeni,</i>	
Therapeutic Potential of Nitric Oxide Donors in Cancer: Focus on Angiogenesis	447
<i>L. Morbidelli</i>	

CRITICAL REVIEWS™ IN ONCOGENESIS

AUTHOR INDEX VOLUME 21, 2016

Page Range of Issues:

Issues 1-2: 1-154; Issue 3-4: 155-308; Issue 5-6: 309-458

Amersi, F., 105	Girotti, A.W., 353	Morbidelli, L., 447
Bachert, E., 309	Glynn, S.A., 333	Muntané, J., 413
Balcer-Kubiczek, E.K., 169	González, R., 413	Murphy, B.M. 241
Balch, C.M., 3	Grimm, E.A., 57	Navarro-Villarán, E., 413
Barry, S.E., 253	Grynspan, D., 221	Nieweg, O.E., 7
Bauer, G., 365	Guo, S., 467	Nonnenmacher, L., 253
Bazzani, L., 325	Guo, W., 383	Noonan, J., 241
Bettaieb, A., 399	Halatsch, M-E., 253	Ollilaa, D.W., 37
Bouaouiche, S., 399	Hall, C., 125	Padillo, F.J., 413
Brühl, O., 253	Hasslacher, S., 253	Pennati, M., 269
Burack, W.R., 527	He, F., 383	Philchenkov, A., 185
Burster, T., 253	He, X., 383	Plenchette, S., 399
Callagy, G., 333	Holcik, M., 221	Rapozzi, V., v, 309
Cao, Z., 155	Hoon, D.S.B., 1, 3, 141	Reed, D., 25
Cassinelli, G. 269	Hsueh E.C., 37	Rizza, S., 433
Chen, J., 407	Huynh, K., 141	Rodríguez-Hernández, M.A., 413
Chen, N., 383	Irie, R.F., 75	Roth, J., 115
Chen, S.L., 19	Jones, P.C., 75	Safa, A.R., 203
Cimino-Reale, G., 269	Karpel-Massler, G., 253	Siegelin, M.D., 253
Colquhoun, S.D., 93	Keane, M.M., 333	Silberman, A.W., 105
Cowan, K.N., 221	Kelley, M.C., 83	Sondak, V.K., 25
Debatin, K-M, 253	Kyprianou, N., 155	Terzuoli, E., 325
Ding, Y., 527	La Ferla-Brühl, K., 253	Thompson, J.F., 7
Dobson, C.C., 221	Langlois, S., 221	Uren, R.F., 7
Donnini, S., 325	Lara-Guerra, H., 115	Valad, L., 125
Dubrez, L., 399	Liu, J., 407	Varchi, G., v, 309
Faries, M.B., 65	Livas, T., 155	Walsh, E.M., 333
Ferroni, C., 309	Lopez, N.E., 37	Westhoff, M-A, 253
Filomeni, G., 433	Lucci, A., 125	Wink, D.A., 333
Forscher, C., 105	Messina, J.L., 25	Zarrer, J., 241
Gasparrini, S., 395	Miura, K., 185	Ziche, M., 325
Gatti, L., 269	Molina-Ruiz, F.J., 413	Zimmermann, J., 253

CRITICAL REVIEWS™ IN ONCOGENESIS

SUBJECT INDEX VOLUME 21, 2016

Page Range of Issues:

Issues 1-2: 1-154; Issue 3-4: 155-308; Issue 5-6: 309-458

- angiogenesis, 447
anoikis, 155
antibody, 75
antitumoral activity, 413
apoptosis resistance, 203, 353
apoptosis, 169, 185, 221, 253, 269, 365, 447
autophagy, 241, 413
Bcl-2 family, 203
blood, 141
BRAF, 83
breast cancer, 19, 125
cancer, 185, 241, 309
cancer metabolism, 433
cancer therapy, 253
carcinogenesis, 169, 367
catalase, 365
CD74, 57
cell death, 185, 241
cell survival, 185, 241
cell-free DNA 141
cellular FLICE (c-FLIP), 203
cellular inhibitor of apoptosis proteins (cIAP), 221
chemotherapy, 333
childhood cancer, 221
circulating tumor cells, 125, 141, 345
clinical trials, 185
conjugate, 309
cytokines, 57
Darwinian principles, 253
death receptors, 203
DNA repair, 433
drug resistance, 269
epidermal growth factor receptor (EGFR), 325, 333
epigenetics, 269
epithelial mesenchymal transition, 155
epithelial-to-mesenchymal ganglioside, 75
gene therapy, 115
glioblastoma, 241
G-quadruplex, 269
hepatitis B virus, 93
hepatocellular carcinoma, 93, 413
hydroxyl radical, 365
hyperaggressiveness, 353
IgM, 75
immune, 83
immunotherapy, 37, 65
inducible nitric oxide synthases (iNOS), 57, 353
inflammation, 309
inhibitor of apoptosis (IAP), 185, 399
inhibitors, 353
integrin, 155
internal initiation of translation, 221
intralesional, 65
liquid biopsy, 45, 141
liver transplantation, 93
lung cancer, 115
lymphadenectomy, 19
melanoma, 7, 25, 37, 65, 83, 141
metastasectomy, 37
metastasis, 141
molecular targets, 333
multidrug resistance, 203
neoadjuvant, 37
nitric oxide (NO), 57, 309, 325, 333, 353, 365, 399, 447
nitric oxide donors, 309, 447
nitric oxide hybrids, 447
nitrosative stress, 413
nuclear factor-kappa B (NF-κB), 399
nucleic acids, 269
O⁶-alkylguanine-DNA alkyltransferase (AGT), 433
oncogene promoters, 269
oncogenesis, 399
Outcomes, 105
pediatric atypical melanocytic neoplasms, 25
peroxynitrite, 365
phosphate dehydrogenase (GSNOR), 433
photodynamic therapy, 353
platinum, 333
prostaglandin E 2 (PGE-2), 325
prostate tumor, 155
radiation, 169
receptor tyrosine kinases, 269
response, 83
Retroperitoneal Sarcomas, 105
second mitochondria-derived activator of caspases (SMAC), 185
sentinel lymph node, 7, 19, 25
singlet oxygen, 365
S-nitrosoglutathione reductase (GSNOR), 309
S-nitrosylation, 433
sorafenib, 413
staging, 7
succinate dehydrogenase (SDH), 433
superoxide dismutase (SOD), 365
Surgery, 105
surgical oncology, 7
survival pathways, 269
talin, 155
targeted therapy, 37, 83
taxanes, 333
therapeutic endpoints, 253
TNF receptor-associated protein 1 (TRAP1), 433
triple negative breast cancer (TNBC), 333
tumor, 75
tumor angiogenesis, 325
tumor ecosystem, 253
tumor growth, 325, 447
tumor suppressor, 433
ubiquitin-proteasome, 269
unfolded protein response, 269